2-piperidinyl substituted N,3-dihydroxybutanamides
View Patent ↗Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R 1 , R 2 , Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
1. A compound that is:
or pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, solvent, adjuvant or diluent.
3. A method of treating Gram-negative bacterial infections, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to claim 1 .
4. A method of inhibiting a deacetylase enzyme in Gram-negative bacteria, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to claim 1 .
5. A compound of formula:
or a pharmaceutically acceptable salt thereof, wherein
R 1 is hydrogen; and
R 2 is
6. A compound according to claim 5 , wherein the compound is of formula:
7. A compound according to claim 5 , wherein R 2 represents
8. A compound according to claim 5 , wherein R 2 represents
9. A compound according to claim 5 that is:
or pharmaceutically acceptable salts thereof.
10. A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier, solvent, adjuvant or diluent.
11. A method of treating Gram-negative bacterial infections, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to claim 5 .
12. A method of inhibiting a deacetylase enzyme in Gram-negative bacteria, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to claim 5 .
13. A compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein
Y represents phenyl optionally substituted with R 4 ;
Z represents phenyl optionally substituted with R 5 ;
R 1 is hydrogen;
R 2 is
each R 4 is independently selected from the group consisting of halogen, —NO 2 , —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —OH, C 1 -C 6 alkoxy, and C 1 -C 6 haloalkoxy; and
each R 5 is independently selected from the group consisting of halogen, —NO 2 , —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —OH, C 1 -C 6 alkoxy, and C 1 -C 6 haloalkoxy.
14. A compound according to claim 13 , wherein R 2 represents
15. A pharmaceutical composition comprising a compound according to claim 13 and a pharmaceutically acceptable carrier, solvent, adjuvant or diluent.
16. A method of treating Gram-negative bacterial infections, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to claim 13 .
17. A method of inhibiting a deacetylase enzyme in Gram-negative bacteria, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to claim 13 .